NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘ARCH Venture Partners’

22 December 2014

VC-backed Juno Therapeutics raises $264.5m at IPO

money-in-hand-1035691-m Arch Venture Partners-backed cancer fighting company Juno Therapeutics has raised $264.5m after pricing its shares at $24m.

28 October 2014

Syros lands $53m from eight VC firms

pills-pills-pills-4-606633-m Eight venture capital firms have participated in a $53m Series B financing round for gene control therapies company Syros Pharmaceuticals.

27 August 2014

Arch Venture Partners raises more than $400m for latest fund

chicagooo Chicago-based venture capital firm Arch Venture Partners has closed its eighth fund on more than $400m, easily beating its $250m target.

7 August 2014

Venture capital-backed Juno Therapeutics raises $134m Series B

cancer juno Venture capital-backed biotechnology startup Juno Therapeutics has raised $134m in its Series B round to fund the development of its immunotherapies for cancer.

29 July 2014

Accelerator holds $51.1m first close for life science venture capital Fund IV

news_dollars3_lrg Biotech venture capital firm Accelerator Corporation has announced a $51.1m first closing of its fourth fund.

27 May 2014

Tao Invest leads Twist Bioscience’s $26m Series B

twist San Francisco-based synthetic DNA producer Twist Bioscience has secured $26m in a Series B round led by Tao Invest.

19 May 2014

Sorbent Therapeutics secures $6.5m

medical monitor Biopharmaceutical startup Sorbent Therapeutics, which is focused on developing therapies for cardiovascular and renal diseases, has closed a $6.5m tranche in its $15m Series D funding round.

24 April 2014

ARCH Ventures back in the market for $250m eighth fundp

Menz-Holz-rose-arch Veteran venture capital investor ARCH Venture Partners has launched its eighth fundraise with its eye on up to $250m of new capital, AltAssets can reveal.

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

24 December 2013

Madison Dearborn nears $1.5bn Ikaria buyout from PE, venture firms

drug-pharma-medical-healthcare US buyout house Madison Dearborn Partners is reportedly nearing a $1.5bn-plus deal to buy private equity and venture capital-backed drug business Ikaria.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015